Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the ...

Exact Sciences secures colorectal cancer test rights from Freenome in a $75M agreement with up to $700M milestone payouts.

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November.

Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Deal worth up to $885 million based on achievement of certain regulatory and screening guideline milestones –  – Availability of real-world patient and multimodal molecular data will feed AI/ML models ...

Q2 2025 Earnings Call Transcript August 6, 2025 Exact Sciences Corporation beats earnings expectations. Reported EPS is $0.22 ...

Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...

Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q2 CY2025, with sales ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...